Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 · New England Journal of Medicine · 9,911 citations
https://doi.org/10.1056/nejmoa1606774
R
Rina Hui
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
252
Papers
47.2K
Citations
63
h-index
130
i10-index
Rina Hui is an academic researcher from The University of Sydney. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & Lung Cancer Diagnosis and Treatment. The author has an h-index of 63, co-authored 215 publications.
ORCID: 0000-0003-0696-7442Papers by this author
worksPembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
2018 · New England Journal of Medicine · 6,385 citations
https://doi.org/10.1056/nejmoa1801005
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
2015 · New England Journal of Medicine · 6,155 citations
https://doi.org/10.1056/nejmoa1501824
Pembrolizumab for Early Triple-Negative Breast Cancer
2020 · New England Journal of Medicine · 2,944 citations
https://doi.org/10.1056/nejmoa1910549
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
2019 · Journal of Thoracic Oncology · 423 citations
https://doi.org/10.1016/j.jtho.2019.10.002
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
2024 · New England Journal of Medicine · 310 citations
https://doi.org/10.1056/nejmoa2409932
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat